Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT01959698 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT01959698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01959698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 17, 2014
Completion date
December 1, 2026
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd20 positive, recurrent diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, stage i diffuse large b-cell lymphoma, stage ii diffuse large b-cell lymphoma, stage iii diffuse large b-cell lymphoma, stage iv diffuse large b-cell lymphoma